vs
ARDELYX, INC.（ARDX）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
ARDELYX, INC.的季度营收约是REGIS CORP的1.7倍（$94.5M vs $57.1M），REGIS CORP净利率更高（0.8% vs -39.8%，领先40.6%），ARDELYX, INC.同比增速更快（27.5% vs 22.3%），过去两年ARDELYX, INC.的营收复合增速更高（13.6% vs 7.8%）
Ardelyx是一家商业化阶段的生物制药企业，专注于研发和商业化针对胃肠道、心肾及代谢类疾病的创新疗法，其核心产品已在美国获批用于治疗便秘型肠易激综合征，同时拥有涵盖多适应症的各阶段研发管线。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
ARDX vs RGS — 直观对比
营收规模更大
ARDX
是对方的1.7倍
$57.1M
营收增速更快
ARDX
高出5.2%
22.3%
净利率更高
RGS
高出40.6%
-39.8%
两年增速更快
ARDX
近两年复合增速
7.8%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $94.5M | $57.1M |
| 净利润 | $-37.6M | $456.0K |
| 毛利率 | — | — |
| 营业利润率 | — | 10.8% |
| 净利率 | -39.8% | 0.8% |
| 营收同比 | 27.5% | 22.3% |
| 净利润同比 | — | -94.0% |
| 每股收益（稀释后） | $-0.15 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARDXRGS
| Q1 26 | $94.5M | — | ||
| Q4 25 | $125.2M | $57.1M | ||
| Q3 25 | $110.3M | $59.0M | ||
| Q2 25 | $97.7M | $60.4M | ||
| Q1 25 | $74.1M | $57.0M | ||
| Q4 24 | $116.1M | $46.7M | ||
| Q3 24 | $98.2M | $46.1M | ||
| Q2 24 | $73.2M | $49.4M |
净利润ARDXRGS
| Q1 26 | $-37.6M | — | ||
| Q4 25 | $-407.0K | $456.0K | ||
| Q3 25 | $-969.0K | $1.4M | ||
| Q2 25 | $-19.1M | $116.5M | ||
| Q1 25 | $-41.1M | $250.0K | ||
| Q4 24 | $4.6M | $7.6M | ||
| Q3 24 | $-809.0K | $-853.0K | ||
| Q2 24 | $-16.5M | $91.2M |
毛利率ARDXRGS
| Q1 26 | — | — | ||
| Q4 25 | 91.3% | — | ||
| Q3 25 | 96.4% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.4% | — | ||
| Q4 24 | 84.3% | — | ||
| Q3 24 | 84.0% | — | ||
| Q2 24 | 87.1% | — |
营业利润率ARDXRGS
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | 10.8% | ||
| Q3 25 | 4.2% | 10.0% | ||
| Q2 25 | -14.7% | 12.1% | ||
| Q1 25 | -49.0% | 8.8% | ||
| Q4 24 | 7.0% | 11.8% | ||
| Q3 24 | 2.3% | 4.6% | ||
| Q2 24 | -18.6% | — |
净利率ARDXRGS
| Q1 26 | -39.8% | — | ||
| Q4 25 | -0.3% | 0.8% | ||
| Q3 25 | -0.9% | 2.3% | ||
| Q2 25 | -19.5% | 192.9% | ||
| Q1 25 | -55.5% | 0.4% | ||
| Q4 24 | 4.0% | 16.4% | ||
| Q3 24 | -0.8% | -1.9% | ||
| Q2 24 | -22.5% | 184.7% |
每股收益（稀释后）ARDXRGS
| Q1 26 | $-0.15 | — | ||
| Q4 25 | $-0.01 | $0.16 | ||
| Q3 25 | $0.00 | $0.49 | ||
| Q2 25 | $-0.08 | $43.67 | ||
| Q1 25 | $-0.17 | $0.08 | ||
| Q4 24 | $0.01 | $2.71 | ||
| Q3 24 | $0.00 | $-0.36 | ||
| Q2 24 | $-0.07 | $38.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $238.1M | $18.4M |
| 总债务越低越好 | $203.5M | $113.3M |
| 股东权益账面价值 | $148.6M | $188.7M |
| 总资产 | $504.5M | $588.3M |
| 负债/权益比越低杠杆越低 | 1.37× | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资ARDXRGS
| Q1 26 | $238.1M | — | ||
| Q4 25 | $68.0M | $18.4M | ||
| Q3 25 | $42.7M | $16.6M | ||
| Q2 25 | $90.0M | $17.0M | ||
| Q1 25 | $30.8M | $13.3M | ||
| Q4 24 | $64.9M | $10.2M | ||
| Q3 24 | $47.4M | $6.3M | ||
| Q2 24 | $41.9M | $10.1M |
总债务ARDXRGS
| Q1 26 | $203.5M | — | ||
| Q4 25 | $202.8M | $113.3M | ||
| Q3 25 | $202.1M | $111.3M | ||
| Q2 25 | $201.4M | $110.8M | ||
| Q1 25 | $151.3M | $112.0M | ||
| Q4 24 | $150.9M | $111.5M | ||
| Q3 24 | $100.7M | $95.2M | ||
| Q2 24 | $100.2M | $99.5M |
股东权益ARDXRGS
| Q1 26 | $148.6M | — | ||
| Q4 25 | $166.9M | $188.7M | ||
| Q3 25 | $154.3M | $187.6M | ||
| Q2 25 | $139.5M | $185.6M | ||
| Q1 25 | $145.7M | $68.6M | ||
| Q4 24 | $173.3M | $66.7M | ||
| Q3 24 | $158.3M | $56.4M | ||
| Q2 24 | $147.0M | $56.8M |
总资产ARDXRGS
| Q1 26 | $504.5M | — | ||
| Q4 25 | $501.6M | $588.3M | ||
| Q3 25 | $486.2M | $592.1M | ||
| Q2 25 | $466.8M | $599.0M | ||
| Q1 25 | $410.2M | $511.2M | ||
| Q4 24 | $435.8M | $530.1M | ||
| Q3 24 | $367.9M | $508.9M | ||
| Q2 24 | $343.5M | $530.5M |
负债/权益比ARDXRGS
| Q1 26 | 1.37× | — | ||
| Q4 25 | 1.21× | 0.60× | ||
| Q3 25 | 1.31× | 0.59× | ||
| Q2 25 | 1.44× | 0.60× | ||
| Q1 25 | 1.04× | 1.63× | ||
| Q4 24 | 0.87× | 1.67× | ||
| Q3 24 | 0.64× | 1.69× | ||
| Q2 24 | 0.68× | 1.75× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $1.7M |
| 自由现金流经营现金流 - 资本支出 | — | $891.0K |
| 自由现金流率自由现金流/营收 | — | 1.6% |
| 资本支出强度资本支出/营收 | — | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | — | $14.9M |
8季度趋势，按日历期对齐
经营现金流ARDXRGS
| Q1 26 | — | — | ||
| Q4 25 | $21.0M | $1.7M | ||
| Q3 25 | $365.0K | $2.3M | ||
| Q2 25 | $-25.3M | $6.8M | ||
| Q1 25 | $-38.5M | $6.2M | ||
| Q4 24 | $9.8M | $2.1M | ||
| Q3 24 | $501.0K | $-1.3M | ||
| Q2 24 | $-19.4M | $5.1M |
自由现金流ARDXRGS
| Q1 26 | — | — | ||
| Q4 25 | $20.6M | $891.0K | ||
| Q3 25 | $209.0K | $1.9M | ||
| Q2 25 | $-26.0M | $6.2M | ||
| Q1 25 | $-38.8M | $5.9M | ||
| Q4 24 | $9.2M | $1.7M | ||
| Q3 24 | $364.0K | $-1.4M | ||
| Q2 24 | $-19.5M | $5.1M |
自由现金流率ARDXRGS
| Q1 26 | — | — | ||
| Q4 25 | 16.4% | 1.6% | ||
| Q3 25 | 0.2% | 3.2% | ||
| Q2 25 | -26.6% | 10.3% | ||
| Q1 25 | -52.3% | 10.3% | ||
| Q4 24 | 7.9% | 3.6% | ||
| Q3 24 | 0.4% | -3.0% | ||
| Q2 24 | -26.7% | 10.3% |
资本支出强度ARDXRGS
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 1.4% | ||
| Q3 25 | 0.1% | 0.7% | ||
| Q2 25 | 0.7% | 0.9% | ||
| Q1 25 | 0.4% | 0.6% | ||
| Q4 24 | 0.5% | 0.9% | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 0.2% | 0.0% |
现金转化率ARDXRGS
| Q1 26 | — | — | ||
| Q4 25 | — | 3.65× | ||
| Q3 25 | — | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | 2.11× | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARDX
| IBSRELA | $70.1M | 74% |
| XPHOZAH | $23.3M | 25% |
| Non-cash royalty revenue related to the sale of future royalties | $695.0K | 1% |
| Product supply revenue | $354.0K | 0% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
